KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bionano Genomics (BNGO) Income from Continuing Operations (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Income from Continuing Operations for 9 consecutive years, with 7933000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 61.42% to 7933000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 26395000.0 through Dec 2025, up 76.53% year-over-year, with the annual reading at 26395000.0 for FY2025, 76.53% up from the prior year.
  • Income from Continuing Operations hit 7933000.0 in Q4 2025 for Bionano Genomics, up from 8503000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 3102000.0 in Q1 2025 to a low of 112566000.0 in Q3 2023.
  • Historically, Income from Continuing Operations has averaged 28818700.0 across 5 years, with a median of 26450500.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 253.88% in 2023 and later skyrocketed 90.13% in 2025.
  • Year by year, Income from Continuing Operations stood at 22949000.0 in 2021, then plummeted by 68.53% to 38677000.0 in 2022, then fell by 13.48% to 43891000.0 in 2023, then skyrocketed by 53.15% to 20563000.0 in 2024, then soared by 61.42% to 7933000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BNGO at 7933000.0 in Q4 2025, 8503000.0 in Q3 2025, and 6857000.0 in Q2 2025.